Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

September 23, 2019 Issue

09737-cover-opener.jpg

September 23, 2019 Cover

Volume 97, Issue 37

After decades of failures, the first wave of KRAS G12C inhibitors has reached the clinic. Can the feat be repeated with other RAS proteins?

Cover image:After decades of failures, the first wave of KRAS G12C inhibitors has reached the clinic. Can the feat be repeated with other RAS proteins?

Credit: Will Ludwig/ C&EN/ Amgen

Full Article
  • At chemical maker Nouryon, the transformation begins

    Former AkzoNobel business eyes billion-dollar acquisitions, expansions, and divestments

  • Meet the group providing science and technology information to the US Congress

    The Government Accountability Office aims to improve quality, timeliness of reports on emerging disruptive technologies

ADVERTISEMENT
image name
Cancer

Some anticancer molecules are off target

Experiments in cell lines suggest that the molecules kill cancer cells through targets they weren’t designed to hit

ADVERTISEMENT
ADVERTISEMENT